PHK
KLRS

Point72 Hong Kong’s Kalaris Therapeutics KLRS Stock Holding History

Point72 Hong Kong’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-202
Closed -$18K – 2489
2022
Q2 		$18K Buy
202
+98
+94% +$10.3K ﹤0.01% 1587
2022
Q1 		$16K Buy
104
+40
+63% +$7.98K ﹤0.01% 1558
2021
Q4 		$19K Buy
+64
New +$29.7K ﹤0.01% 1548
2021
Q3 		– Sell
-5
Closed -$2K – 2524
2021
Q2 		$2K Sell
5
-15
-75% -$7.75K ﹤0.01% 1840
2021
Q1 		$11K Buy
+20
New +$16.8K ﹤0.01% 1579

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Hong Kong's KLRS Position: Q3 2022 in Review

Point72 Hong Kong sold out of Kalaris Therapeutics (KLRS) in Q3 2022, closing a stake of 202 shares — an estimated $18K sold.

Point72 Hong Kong first reported a position in KLRS in Q1 2021 and held it in 5 quarters. The position peaked at $19K in Q4 2021. 85 funds tracked by Wall St. Rank hold KLRS as of Q3 2022.

  • Point72 Hong Kong reported no remaining Kalaris Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 202 Kalaris Therapeutics shares in Q3 2022, an estimated $18K.
  • Point72 Hong Kong first reported a position in Kalaris Therapeutics in Q1 2021 and held it in 5 quarters.
  • Point72 Hong Kong's Kalaris Therapeutics position peaked at $19K in Q4 2021.
  • 85 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2022.

Based on Point72 Hong Kong's 13F filing for Q3 2022, filed 14 Nov 2022.